{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:44:40Z","timestamp":1792183480973,"version":"4.4.0"},"reference-count":63,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T00:00:00Z","timestamp":1716336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Israeli Association of Gastroenterology"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nutrients"],"abstract":"<jats:p>Several studies show that gut microbiotas in patients with nonalcoholic fatty liver disease (NAFLD) differ from those in a healthy population, suggesting that this alteration plays a role in NAFLD pathogenesis. We investigated whether prebiotic administration affects liver fat content and\/or liver-related and metabolic parameters. Patients with NAFLD and metabolic syndrome (age: 50 \u00b1 11; 79% men) were randomized to receive either 16 g\/day of prebiotic (ITFs\u2014inulin-type fructans) (n = 8) or placebo (maltodextrin) (n = 11) for 12 weeks. Patients were instructed to maintain a stable weight throughout the study. Liver fat content (measured by H1MRS), fecal microbiota, and metabolic, inflammatory, and liver parameters were determined before and after intervention. Fecal samples from patients who received the prebiotic had an increased content of Bifidobacterium (p = 0.025), which was not observed with the placebo. However, the baseline and end-of-study liver fat contents did not change significantly in the prebiotic and placebo groups, neither did the liver function tests\u2019 metabolic and inflammatory mediators, including fibroblast growth factor-19 and lipopolysaccharide-binding protein. Body weight remained stable in both groups. These findings suggest that prebiotic treatment without weight reduction is insufficient to improve NAFLD.<\/jats:p>","DOI":"10.3390\/nu16111571","type":"journal-article","created":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T11:03:47Z","timestamp":1716375827000},"page":"1571","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Prebiotic Treatment in Patients with Nonalcoholic Fatty Liver Disease (NAFLD)\u2014A Randomized Pilot Trial"],"prefix":"10.3390","volume":"16","author":[{"given":"Naama","family":"Reshef","sequence":"first","affiliation":[{"name":"Institute of Diabetes and Metabolism-Kaplan Medical Center, Rehovot 7661041, Israel"},{"name":"School of Nutritional Sciences, Faculty of Agriculture, Food and Environment, The Hebrew University, Jerusalem 9112102, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5129-5652","authenticated-orcid":false,"given":"Uri","family":"Gophna","sequence":"additional","affiliation":[{"name":"Shmunis School of Biomedicine and Cancer Research, Faculty of Life Sciences, Tel-Aviv University, Tel Aviv 6423906, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah","family":"Reshef","sequence":"additional","affiliation":[{"name":"Shmunis School of Biomedicine and Cancer Research, Faculty of Life Sciences, Tel-Aviv University, Tel Aviv 6423906, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Konikoff","sequence":"additional","affiliation":[{"name":"Institute of Gastroenterology and Hepatology-Meir Medical Center, Kefar Sava 4428164, Israel"},{"name":"Faculty of Medicine, Tel-Aviv University, Tel Aviv 6423906, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gila","family":"Gabay","sequence":"additional","affiliation":[{"name":"Institute of Gastroenterology and Hepatology-Meir Medical Center, Kefar Sava 4428164, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiba","family":"Zornitzki","sequence":"additional","affiliation":[{"name":"Institute of Diabetes and Metabolism-Kaplan Medical Center, Rehovot 7661041, Israel"},{"name":"Hadassah School of Medicine, The Hebrew University, Jerusalem 9112102, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilla","family":"Knobler","sequence":"additional","affiliation":[{"name":"Institute of Diabetes and Metabolism-Kaplan Medical Center, Rehovot 7661041, Israel"},{"name":"Hadassah School of Medicine, The Hebrew University, Jerusalem 9112102, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaakov","family":"Maor","sequence":"additional","affiliation":[{"name":"Hadassah School of Medicine, The Hebrew University, Jerusalem 9112102, Israel"},{"name":"Institute of Gastroenterology and Hepatology-Kaplan Medical Center, Rehovot 7661043, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,5,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.3350\/cmh.2022.0365","article-title":"Global incidence and prevalence of nonalcoholic fatty liver disease","volume":"29","author":"Teng","year":"2023","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Calzadilla Bertot, L., and Adams, L.A. (2016). The Natural Course of Non-Alcoholic Fatty Liver Disease. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17050774"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1093\/qjmed\/hcg120","article-title":"Non-alcoholic fatty liver: A common manifestation of a metabolic disorder","volume":"96","author":"Malnick","year":"2003","journal-title":"QJM"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"101138","DOI":"10.1016\/j.aohep.2023.101138","article-title":"Metabolic dysfunction: The silenced connection with fatty liver disease","volume":"28","author":"Qi","year":"2023","journal-title":"Ann. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"197","DOI":"10.7570\/jomes23052","article-title":"Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review","volume":"32","author":"Chan","year":"2023","journal-title":"J. Obes. Metab. Syndr."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Gupta, H., Min, B.-H., Ganesan, R., Gebru, Y.A., Sharma, S.P., Park, E., Won, S.-M., Jeong, J.-J., Lee, S.-B., and Cha, M.-G. (2022). Gut Microbiome in Non-Alcoholic Fatty Liver Disease: From Mechanisms to Therapeutic Role. Biomedicines, 10.","DOI":"10.3390\/biomedicines10030550"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/nrgastro.2016.85","article-title":"The role of the gut microbiota in NAFLD","volume":"13","author":"Leung","year":"2016","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.cmet.2017.04.001","article-title":"Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease","volume":"25","author":"Loomba","year":"2017","journal-title":"Cell Metab."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/hep.26093","article-title":"Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: A connection between endogenous alcohol and NASH","volume":"57","author":"Zhu","year":"2013","journal-title":"Hepatology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1038\/s41591-018-0169-5","article-title":"Publisher Correction: Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women","volume":"24","author":"Hoyles","year":"2018","journal-title":"Nat. Med."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Zhu, M., Dagah, O.M.A., Silaa, B.B., and Lu, J. (2023). Thioredoxin\/glutaredoxin systems and gut microbiota in NAFLD: Interplay, mechanism, and therapeutical potential. Antioxidants, 12.","DOI":"10.3390\/antiox12091680"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Carpi, R.Z., Barbalho, S.M., Sloan, K.P., Laurindo, L.F., Gonzaga, H.F., Grippa, P.C., Zutin, T.L.M., Girio, R.J.S., Repetti, C.S.F., and Detregiachi, C.R.P. (2022). The Effects of Probiotics, Prebiotics and Synbiotics in Non-Alcoholic Fat Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH): A Systematic Review. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23158805"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1007\/s11154-023-09843-z","article-title":"Non-alcoholic fatty liver disease and gut microbial dysbiosis- underlying mechanisms and gut microbiota mediated treatment strategies","volume":"24","author":"Jayachandran","year":"2023","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Chen, J., and Vitetta, L. (2020). Gut microbiota metabolites in NAFLD pathogenesis and therapeutic implications. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21155214"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"12511","DOI":"10.1073\/pnas.0601056103","article-title":"Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice","volume":"103","author":"Dumas","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"544","DOI":"10.3389\/fmed.2020.00544","article-title":"Bile acids and FXR: Novel targets for liver diseases","volume":"7","author":"Stofan","year":"2020","journal-title":"Front. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/MOL.0000000000000599","article-title":"Fibroblast growth factors in control of lipid metabolism: From biological function to clinical application","volume":"30","author":"Struik","year":"2019","journal-title":"Curr. Opin. Lipidol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"601349","DOI":"10.3389\/fendo.2020.601349","article-title":"FGF19 and FGF21 for the Treatment of NASH-Two Sides of the Same Coin? Differential and Overlapping Effects of FGF19 and FGF21 From Mice to Human","volume":"11","author":"Henriksson","year":"2020","journal-title":"Front. Endocrinol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/liv.12531","article-title":"Hepatic toll-like receptor 4 expression is associated with portal inflammation and fibrosis in patients with NAFLD","volume":"35","author":"Carotti","year":"2015","journal-title":"Liver Int."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"29","DOI":"10.4161\/gmic.19246","article-title":"Prebiotic fiber modulation of the gut microbiota improves risk factors for obesity and the metabolic syndrome","volume":"3","author":"Parnell","year":"2012","journal-title":"Gut Microbes"},{"key":"ref_21","first-page":"1935","article-title":"Role and effective therapeutic target of gut microbiota in NAFLD\/NASH","volume":"18","author":"Liu","year":"2019","journal-title":"Exp. Ther. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1093\/nutrit\/nuy031","article-title":"Prebiotic and probiotic treatment of nonalcoholic fatty liver disease: A systematic review and meta-analysis","volume":"76","author":"Loman","year":"2018","journal-title":"Nutr. Rev."},{"key":"ref_23","first-page":"315","article-title":"Inulin-type prebiotics\u2014A review: Part 1","volume":"13","author":"Kelly","year":"2008","journal-title":"Altern. Med. Rev."},{"key":"ref_24","first-page":"36","article-title":"Inulin-type prebiotics: A review. (Part 2)","volume":"14","author":"Kelly","year":"2009","journal-title":"Altern. Med. Rev."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1136\/gutjnl-2012-303304","article-title":"Insight into the prebiotic concept: Lessons from an exploratory, double blind intervention study with inulin-type fructans in obese women","volume":"62","author":"Dewulf","year":"2013","journal-title":"Gut"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.clnu.2014.06.001","article-title":"Inulin-type fructans modulate intestinal Bifidobacterium species populations and decrease fecal short-chain fatty acids in obese women","volume":"34","author":"Salazar","year":"2015","journal-title":"Clin. Nutr."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/sj.ejcn.1602127","article-title":"Effects of oligofructose on glucose and lipid metabolism in patients with nonalcoholic steatohepatitis: Results of a pilot study","volume":"59","author":"Daubioul","year":"2005","journal-title":"Eur. J. Clin. Nutr."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1002\/hep4.1794","article-title":"Definition of healthy ranges for alanine aminotransferase levels: A 2021 update","volume":"5","author":"Valenti","year":"2021","journal-title":"Hepatol. Commun."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1161\/CIRCULATIONAHA.105.169404","article-title":"Diagnosis and management of the metabolic syndrome","volume":"112","author":"Grundy","year":"2005","journal-title":"Circulation"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.1016\/j.celrep.2018.05.018","article-title":"Infant and Adult Gut Microbiome and Metabolome in Rural Bassa and Urban Settlers from Nigeria","volume":"23","author":"Ayeni","year":"2018","journal-title":"Cell Rep."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Fadrosh, D.W., Ma, B., Gajer, P., Sengamalay, N., Ott, S., Brotman, R.M., and Ravel, J. (2014). An improved dual-indexing approach for multiplexed 16S rRNA gene sequencing on the Illumina MiSeq platform. Microbiome, 2.","DOI":"10.1186\/2049-2618-2-6"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nmeth.3869","article-title":"DADA2: High-resolution sample inference from Illumina amplicon data","volume":"13","author":"Callahan","year":"2016","journal-title":"Nat. Methods"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Segata, N., Izard, J., Waldron, L., Gevers, D., Miropolsky, L., Garrett, W.S., and Huttenhower, C. (2011). Metagenomic biomarker discovery and explanation. Genome Biol., 12.","DOI":"10.1186\/gb-2011-12-s1-p47"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1093\/advances\/nmab119","article-title":"The Prebiotic Potential of Inulin-type Fructans: A Systematic Review","volume":"13","author":"Hughes","year":"2021","journal-title":"Adv. Nutr."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1007\/s00394-021-02484-5","article-title":"Prebiotic dietary fibre intervention improves fecal markers related to inflammation in obese patients: Results from the Food4Gut randomized placebo-controlled trial","volume":"60","author":"Neyrinck","year":"2021","journal-title":"Eur. J. Nutr."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1053\/j.gastro.2017.05.055","article-title":"Prebiotics reduce body fat and alter intestinal microbiota in children who are overweight or with obesity","volume":"153","author":"Nicolucci","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"45176","DOI":"10.1038\/srep45176","article-title":"Probiotics may delay the progression of nonalcoholic fatty liver disease by restoring the gut microbiota structure and improving intestinal endotoxemia","volume":"7","author":"Xue","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Kobyliak, N., Falalyeyeva, T., Virchenko, O., Mykhalchyshyn, G., Bodnar, P., Spivak, M., Yankovsky, D., Beregova, T., and Ostapchenko, L. (2016). Comparative experimental investigation on the efficacy of mono- and multiprobiotic strains in non-alcoholic fatty liver disease prevention. BMC Gastroenterol., 16.","DOI":"10.1186\/s12876-016-0451-2"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e634","DOI":"10.1002\/ctm2.634","article-title":"Lactobacillus lactis and Pediococcus pentosaceus-driven reprogramming of gut microbiome and metabolome ameliorates the progression of non-alcoholic fatty liver disease","volume":"11","author":"Yu","year":"2021","journal-title":"Clin. Transl. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2264737","DOI":"10.1155\/2021\/2264737","article-title":"Probiotics Alleviated Nonalcoholic Fatty Liver Disease in High-Fat Diet-Fed Rats via Gut Microbiota\/FXR\/FGF15 Signaling Pathway","volume":"2021","author":"Luo","year":"2021","journal-title":"J. Immunol. Res."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Plaza-Diaz, J., Gomez-Llorente, C., Abadia-Molina, F., Saez-Lara, M.J., Campa\u00f1a-Martin, L., Mu\u00f1oz-Quezada, S., Romero, F., Gil, A., and Fontana, L. (2014). Effects of Lactobacillus paracasei CNCM I-4034, Bifidobacterium breve CNCM I-4035 and Lactobacillus rhamnosus CNCM I-4036 on hepatic steatosis in Zucker rats. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0098401"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Liu, Q., Liu, Y., Li, F., Gu, Z., Liu, M., Shao, T., Zhang, L., Zhou, G., Pan, C., and He, L. (2020). Probiotic culture supernatant improves metabolic function through FGF21-adiponectin pathway in mice. J. Nutr. Biochem., 75.","DOI":"10.1016\/j.jnutbio.2019.108256"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.bbrc.2022.02.033","article-title":"Inulin activates FXR-FGF15 signaling and further increases bile acids excretion in non-alcoholic fatty liver disease mice","volume":"600","author":"Wang","year":"2022","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Ritze, Y., B\u00e1rdos, G., Claus, A., Ehrmann, V., Bergheim, I., Schwiertz, A., and Bischoff, S.C. (2014). Lactobacillus rhamnosus GG protects against non-alcoholic fatty liver disease in mice. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0080169"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"773340","DOI":"10.3389\/fendo.2021.773340","article-title":"Bifidobacterium adolescentis Alleviates Liver Steatosis and Steatohepatitis by Increasing Fibroblast Growth Factor 21 Sensitivity","volume":"12","author":"Long","year":"2021","journal-title":"Front. Endocrinol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"112309","DOI":"10.1016\/j.foodres.2022.112309","article-title":"Inulin intervention attenuates hepatic steatosis in rats via modulating gut microbiota and maintaining intestinal barrier function","volume":"163","author":"Yang","year":"2023","journal-title":"Food Res. Int."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Mijangos-Trejo, A., Nu\u00f1o-Lambarri, N., Barbero-Becerra, V., Uribe-Esquivel, M., Vidal-Cevallos, P., and Ch\u00e1vez-Tapia, N. (2023). Prebiotics and probiotics: Therapeutic tools for nonalcoholic fatty liver disease. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241914918"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Hu, W., Cassard, A.-M., and Ciocan, D. (2022). Pectin in metabolic liver disease. Nutrients, 15.","DOI":"10.3390\/nu15010157"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Castillo, V., Figueroa, F., Gonz\u00e1lez-Pizarro, K., Jopia, P., and Ibacache-Quiroga, C. (2021). Probiotics and Prebiotics as a Strategy for Non-Alcoholic Fatty Liver Disease, a Narrative Review. Foods, 10.","DOI":"10.3390\/foods10081719"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1007\/s00394-018-1721-2","article-title":"Histological improvement of non-alcoholic steatohepatitis with a prebiotic: A pilot clinical trial","volume":"58","author":"Bomhof","year":"2019","journal-title":"Eur. J. Nutr."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"862266","DOI":"10.3389\/fpubh.2022.862266","article-title":"The promising role of probiotics\/prebiotics\/synbiotics in energy metabolism biomarkers in patients with NAFLD: A systematic review and meta-analysis","volume":"10","author":"Li","year":"2022","journal-title":"Front. Public Health"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1001\/jamainternmed.2019.2248","article-title":"Association of Weight Loss Interventions with Changes in Biomarkers of Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis","volume":"179","author":"Koutoukidis","year":"2019","journal-title":"JAMA Intern. Med."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Mohamad Nor, M.H., Ayob, N., Mokhtar, N.M., Raja Ali, R.A., Tan, G.C., Wong, Z., Shafiee, N.H., Wong, Y.P., Mustangin, M., and Nawawi, K.N.M. (2021). The Effect of Probiotics (MCP\u00ae BCMC\u00ae Strains) on Hepatic Steatosis, Small Intestinal Mucosal Immune Function, and Intestinal Barrier in Patients with Non-Alcoholic Fatty Liver Disease. Nutrients, 13.","DOI":"10.3390\/nu13093192"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1016\/j.tjnut.2023.05.019","article-title":"Probiotic Supplementation, Hepatic Fibrosis, and the Microbiota Profile in Patients with Nonalcoholic Steatohepatitis: A Randomized Controlled Trial","volume":"153","author":"Escouto","year":"2023","journal-title":"J. Nutr."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1053\/j.gastro.2020.01.031","article-title":"Synbiotics alter fecal microbiomes, but not liver fat or fibrosis, in a randomized trial of patients with nonalcoholic fatty liver disease","volume":"158","author":"Scorletti","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"558525","DOI":"10.3389\/fphar.2020.558525","article-title":"Inulin Exerts Beneficial Effects on Non-Alcoholic Fatty Liver Disease via Modulating gut Microbiome and Suppressing the Lipopolysaccharide-Toll-Like Receptor 4-M\u03c8-Nuclear Factor-\u03baB-Nod-Like Receptor Protein 3 Pathway via gut-Liver Axis in Mice","volume":"11","author":"Bao","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s12602-017-9378-3","article-title":"Oral Administration of Compound Probiotics Ameliorates HFD-Induced Gut Microbe Dysbiosis and Chronic Metabolic Inflammation via the G Protein-Coupled Receptor 43 in Non-alcoholic Fatty Liver Disease Rats","volume":"11","author":"Liang","year":"2019","journal-title":"Probiotics Antimicrob. Proteins"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"5688","DOI":"10.1038\/s41598-019-42059-3","article-title":"Randomized, Double-blind, Placebo-controlled Study of a Multispecies Probiotic Mixture in Nonalcoholic Fatty Liver Disease","volume":"9","author":"Ahn","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e000315","DOI":"10.1136\/bmjgast-2019-000315","article-title":"High potency multistrain probiotic improves liver histology in non-alcoholic fatty liver disease (NAFLD): A randomised, double-blind, proof of concept study","volume":"6","author":"Duseja","year":"2019","journal-title":"BMJ Open Gastroenterol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.cmet.2016.05.005","article-title":"Intestinal Crosstalk between Bile Acids and Microbiota and Its Impact on Host Metabolism","volume":"24","author":"Sayin","year":"2016","journal-title":"Cell Metab."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJMoa2304286","article-title":"Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH","volume":"389","author":"Loomba","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S2468-1253(22)00347-8","article-title":"Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: A randomised, double-blind, placebo-controlled, phase 1b\/2a multiple-ascending-dose study","volume":"8","author":"Loomba","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/mrm.20825","article-title":"Hepatic lipid accumulation in healthy subjects: A comparative study using spectral fat-selective MRI and volume-localized 1H-MR spectroscopy","volume":"55","author":"Machann","year":"2006","journal-title":"Magn. Reson. Med."}],"container-title":["Nutrients"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6643\/16\/11\/1571\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:46:46Z","timestamp":1760107606000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6643\/16\/11\/1571"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,22]]},"references-count":63,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["nu16111571"],"URL":"https:\/\/doi.org\/10.3390\/nu16111571","relation":{},"ISSN":["2072-6643"],"issn-type":[{"value":"2072-6643","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,22]]}}}